Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
On 6ix: 6ix.com/news/ardelyx-announces-positive-second-data-analysis-from-ongoing-normalize-phase-4-study
Watch Ardelyx's latest callArdelyx (NASDAQ:ARDX) Q2 2026 Earnings Call · Replay · Aug 6Read the transcript of Ardelyx (NASDAQ:ARDX) Q2 2026 Earnings CallArdelyx's next earnings callArdelyx (NASDAQ:ARDX) Q3 2026 Earnings Call · Nov 3, 2026 at 4:30 PM ESTRegister
Story so far
- Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
- Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Earlier from Ardelyx
- Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
- Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
- Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
- Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights
- Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
Later from Ardelyx
- Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
- Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
- Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
- Ardelyx to Participate in Three Upcoming Investor Conferences in September
- Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
Follow Ardelyx into a list and get an email when it puts out news.
Follow Ardelyx